News Drug Development

Roche Drugs RG1678 Show Promise Treating Schizophrenia, Blood Cancer in Mid-Stage Studies

December 6, 2010 |

1 min read

ZURICH Dec 6 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX) presented the results of studies on two drugs in mid-stage development that may go some way towards addressing concerns about the strength of the company’s drug pipeline.

Clinical research Phase II Europe

Roche

MORE ON THIS TOPIC

vintage textured collage with symbols of New York City

Tariffs

Biotech’s Next Phase Will Be All-American: Pitchbook

April 17, 2025

·

2 min read

·

Annalee Armstrong

Closeup of businessman give money to robot. Man pass banknote bribe to robotic assistant. AI and technology. Vector illustration.

Artificial intelligence

Sanofi Bets More Than $1.8 Billion in Biobucks on AI-Developed Bispecifics

April 17, 2025

·

2 min read

·

Dan Samorodnitsky

Profit and Money Concept, Financial and Business Graph

GLP-1

Lilly Skyrockets on ‘Injectable-Like Efficacy’ for Oral GLP-1 in Phase III Diabetes Trial

April 17, 2025

·

2 min read

·

Tristan Manalac

Lungs health and pulmonology as a respiratory medicine conept for pulmonary science and lung cancer or respiration disease and bronchi breathing or asthma symbol in a 3D illustration style.

Clinical research

Sanofi’s $1.4B Kymab Bet Falters as Asthma Drug Stumbles in Phase II

April 16, 2025

·

2 min read

·

Tristan Manalac